Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Gynecologic Cancers
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Surgery at high-volume centers is associated with decreased local recurrence risk and improved survival for women with early-stage cervical cancer.
Boost in Frontline Bevacizumab Use in Ovarian Cancer Linked to Guidelines Inclusion
Addition of bevacizumab to NCCN guidelines as a frontline therapy in ovarian cancer spurred more utilization of the drug than did fresh findings from clinical trials.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
A new study challenges the recommended use of cotesting for cervical cancer screening.
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
Next post in Gynecologic Cancer
